Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

The report provides a comprehensive analysis of the genome editing market, focusing on technologies like CRISPR-Cas, TALEN, ...

MB-111 is a potential first-in-class, single-dose in vivo CRISPR gene editing therapy for persistent chylomicronemiaOral presentation highlights safe, robust, and durable reduction of apoC-III and ...

With several disease-modifying therapies available for transthyretin amyloid cardiomyopathy (ATTR-CM) -- and more waiting in ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, ...

A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...

The entire rationale behind this multi-pronged screening was the discovery of checkpoints or regulators that are critically involved in inducing suppression in NK cells under these diverse negative ...

MB-111 is a potential first-in-class, single-dose in vivo CRISPR gene editing therapy for persistent chylomicronemia Oral presentation highlights safe, robust, and durable reduction of apoC-III ...

A single one-time gene therapy could free patients with α-thalassemia, a rare and debilitating blood disorder, from the ...